These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38357093)

  • 1. Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.
    Fletcher JA; Mullally WJ; Ladwa R; O'Byrne KJ
    JTO Clin Res Rep; 2024 Feb; 5(2):100591. PubMed ID: 38357093
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with
    Myall NJ; Lei AQ; Wakelee HA
    Transl Lung Cancer Res; 2021 Jan; 10(1):487-495. PubMed ID: 33569330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
    Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
    Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
    Makimoto G; Kawakado K; Nakanishi M; Tamura T; Kuyama S
    Case Rep Oncol; 2021; 14(1):197-201. PubMed ID: 33776703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in
    Zhu VW; Nagasaka M; Kubota T; Raval K; Robinette N; Armas O; Al-Holou W; Ou SI
    Lung Cancer (Auckl); 2020; 11():13-18. PubMed ID: 32021525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
    Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
    Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Sagara H
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
    Yun KM; Bazhenova LA
    Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
    Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
    J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With
    Goto Y; Kenmotsu H; Tamiya M; Murakami S; Kurata T; Yanagitani N; Taniguchi H; Kuyama S; Shimizu J; Yokoyama T; Shimada N; Maeda T; Tamiya A; Uchiyama A; Imaizumi K; Takahama T; Kato T; Hayashi H; Shiraiwa N; Toyoizumi S; Kikkawa H; Thomaidou D; Nishio M
    JTO Clin Res Rep; 2023 May; 4(5):100508. PubMed ID: 37250506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
    Zhao M; Liu S; Xie R; Zhang J; Li J
    Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and clinical properties of lorlatinib in the treatment of
    El Darsa H; Abdel-Rahman O; Sangha R
    Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib for treating patients with metastatic
    Samacá-Samacá D; Prieto-Pinto L; Peréz AY; Valderrama C; Hernández F
    Lung Cancer Manag; 2023 Jun; 12(2):LMT59. PubMed ID: 37287941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.